DE · SRT3.DE · MEDICAL - INSTRUMENTS & SUPPLIES
Sartorius AG (SRT3.DE) intrinsic value and stock valuation
$288.00as of 2026-11-21 · Mkt cap 15.96B
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Sartorius AG DCF and intrinsic value
InvestorsCraft values SRT3.DE with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from SRT3.DE’s statements →
Sartorius AG Graham Number
Graham Number: $53.17d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.54B | $3.38B | $3.4B | $4.17B | $3.45B |
| Operating income | $651.4M | $437.2M | $543.2M | $1.14B | $735.8M |
| Net income | $154.9M | $84M | $205.2M | $913.1M | $427M |
| EPSd | $2.24M | $1.22M | $3M | $13.3M | $6.24M |
| Operating cash flow | $656M | $976.2M | $853.6M | $734.2M | $865.8M |
| Capital expenditure | -$-441.9M | -$-409.9M | -$-559.7M | -$-522.6M | -$-407.17M |
| Free cash flow | $214.1M | $566.3M | $293.9M | $211.6M | $458.7M |
| Total assets | $9.72B | $10.1B | $9.76B | $6.98B | $5.7B |
| Total debt | $4.45B | $4.56B | $5.31B | $2.54B | $2.08B |
| Net debt | $3.91B | $3.75B | $4.93B | $2.38B | $1.73B |
| Total equity | $3.87B | $3.9B | $2.76B | $2.66B | $1.72B |
| Cash and short-term investments | $541.4M | $828.7M | $394.2M | $196.8M | $361M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $3.54B | $3.38B | $3.4B | $4.17B | $3.45B |
| Cost of revenue | $1.9B | $1.86B | $1.83B | $1.98B | $1.61B |
| Gross profit | $1.64B | $1.52B | $1.57B | $2.2B | $1.84B |
| Research and development expenses | $174M | $196.8M | $170.8M | $177.8M | $139.9M |
| Selling, general and administrative expenses | $811.4M | $884M | $848.7M | $829M | $745.7M |
| Other expenses | $0.00 | $6.4M | $4.4M | $13.5M | $20M |
| Operating expenses | $985.4M | $1.09B | $1.02B | $1.02B | $905.6M |
| Cost and expenses | $2.89B | $2.94B | $2.85B | $3B | $2.52B |
| Interest income | $13.9M | $22.1M | $4.6M | $1M | $400K |
| Interest expense | $198M | $205.4M | $156.9M | $67.9M | $45.5M |
| Depreciation and amortization | $420.1M | $415.9M | $341.6M | $287.1M | $231.2M |
| Ebitda | $1.07B | $786.8M | $873.1M | $1.5B | $945.1M |
| Operating income | $651.4M | $437.2M | $543.2M | $1.14B | $735.8M |
| Total other income/expenses, net | -$-314.4M | $0.00 | -$-157.2M | $42.4M | -$-67.4M |
| Income before tax | $337M | $186.8M | $386M | $1.18B | $668.4M |
| Income tax expense | $106.6M | $49.4M | $95.9M | $268.6M | $241.4M |
| Net income | $154.9M | $84M | $205.2M | $913.1M | $427M |
| Weighted average shares outstanding | $69.1M | $69M | $68.4M | $68.4M | $68.4M |
| Weighted average diluted shares outstanding | $69.1M | $69M | $68.4M | $68.4M | $68.4M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $541.4M | $828.7M | $394.2M | $196.8M | $361M |
| Net receivables | $291.7M | $328.7M | $350.6M | $492.9M | $429.3M |
| Inventory | $792.2M | $788.5M | $1.04B | $1.18B | $874.1M |
| Total current assets | $1.77B | $2.11B | $1.96B | $2.02B | $1.8B |
| Property, plant and equipment, net | $2.46B | $2.35B | $2.08B | $1.71B | $1.31B |
| Goodwill and intangible assets | $5.3B | $5.47B | $5.51B | $3B | $2.46B |
| Long-term investments | $67.9M | $66.8M | $114.8M | $120M | $42.7M |
| Total non-current assets | $7.95B | $7.99B | $7.8B | $4.95B | $3.9B |
| Total assets | $9.72B | $10.1B | $9.76B | $6.98B | $5.7B |
| Accounts payable | $343.1M | $344.1M | $306.5M | $551.9M | $515M |
| Short-term debt | $926.4M | $393.1M | $288M | $555M | $337.4M |
| Deferred revenue | $201.9M | $0.00 | $0.00 | $0.00 | $614.5M |
| Total current liabilities | $1.97B | $1.44B | $1.33B | $1.8B | $1.55B |
| Long-term debt | $3.53B | $4.17B | $5.02B | $1.99B | $1.74B |
| Deferred revenue, non-current | $0.00 | $0.00 | -$-200K | $0.00 | $0.00 |
| Total non-current liabilities | $3.88B | $4.76B | $5.66B | $2.52B | $2.43B |
| Capital lease obligations | $171.8M | $181.2M | $147.2M | $143.6M | $115M |
| Total liabilities | $5.85B | $6.21B | $7B | $4.32B | $3.98B |
| Common stock | $69.1M | $69M | $68.4M | $68.4M | $68.4M |
| Retained earnings | $2.49B | $2.39B | $1.97B | $1.83B | $1.17B |
| Accumulated other comprehensive income (loss) | -$-100.3M | $63.9M | -$-18.3M | $50.2M | -$-17.44M |
| Total equity | $3.87B | $3.9B | $2.76B | $2.66B | $1.72B |
| Total investments | $67.9M | $82.1M | $129.8M | $150.9M | $60.9M |
| Total debt | $4.45B | $4.56B | $5.31B | $2.54B | $2.08B |
| Net debt | $3.91B | $3.75B | $4.93B | $2.38B | $1.73B |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | $154.9M | $186.8M | $338.5M | $1.18B | $668.4M |
| Depreciation and amortization | $420.1M | $415.9M | $342.3M | $287.1M | $231.2M |
| Stock-based compensation | $0.00 | $0.00 | $600K | $1M | $3.1M |
| Change in working capital | $4.1M | $277.5M | $144.1M | -$-389.5M | -$-82.23M |
| Accounts receivable | $45.8M | $27.3M | $168.6M | -$-86.6M | -$-99.14M |
| Inventory | -$-48.6M | $258.6M | $118.1M | -$-261.6M | -$-294.41M |
| Accounts payable | $0.00 | $0.00 | $0.00 | $86.6M | $99.1M |
| Net cash provided by operating activities | $656M | $976.2M | $853.6M | $734.2M | $865.8M |
| Investments in property, plant and equipment | -$-441.9M | -$-409.9M | -$-559.7M | -$-522.6M | -$-407.17M |
| Acquisitions, net | -$-66.9M | $0.00 | -$-2.24B | -$-536.1M | -$-141.67M |
| Net cash used for investing activities | -$-513.5M | -$-425.8M | -$-2.82B | -$-1.13B | -$-569.61M |
| Common stock issued | $0.00 | $198.3M | $0.00 | $0.00 | $0.00 |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | -$-50.7M | -$-50.7M | -$-98.2M | -$-85.9M | -$-48.23M |
| Net cash used for financing activities | -$-410.6M | -$-128.3M | $2.17B | $209.9M | -$-165.18M |
| Net change in cash | -$-272M | $434.2M | $213.3M | -$-176.9M | $139.4M |
| Cash at end of period | $541.4M | $813.4M | $379.2M | $165.9M | $342.8M |
| Operating cash flow | $656M | $976.2M | $853.6M | $734.2M | $865.8M |
| Capital expenditure | -$-441.9M | -$-409.9M | -$-559.7M | -$-522.6M | -$-407.17M |
| Free cash flow | $214.1M | $566.3M | $293.9M | $211.6M | $458.7M |
Line items
Line items
Line items
About Sartorius AG
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
- CEO
- Michael Grosse
- Employees
- 13.57K
- Beta
- 1.40
Included in
Explore
Frequently asked questions
What is the intrinsic value of Sartorius AG (SRT3.DE)?
InvestorsCraft does not currently publish an intrinsic value for SRT3.DE. How the IC value is calculated.
Is SRT3.DE undervalued?
InvestorsCraft does not publish an undervaluation signal for SRT3.DE at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.